Introduction: Distant metastases of papillary thyroid carcinoma (PTC) may lack the ability to concentrate radioiodine. In such cases, positive somatostatin receptor scintigraphy might be useful in demonstrating the expression of somatostatin receptors that are potential therapeutic targets. To date, only a few cerebellar metastases from PTC have been reported in the literature.
Introduction
Distant metastases occur rarely in patients with differentiated thyroid carcinoma (DTC). Brain metastases are very rare and cerebellar metastases are extremely rare [1] [2] [3] . Usually brain metastases are detected by means of radioiodine whole-body scan (WBS) or magnetic resonance.
Somatostatin receptor scintigraphy (SRS) using radiolabelled somatostatin analogues has been employed 
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in the evaluation of some patients with advanced DTC with the aim of visualisation of non-iodine avid metastases. In the last decade, Tc-99m-labeled somatostatin analogues were developed, which replaced In-111-DTPA-octreotide (OctreoScan) in some centres [4] [5] [6] . Tc-99m-EDDA/HYNIC-TOC demonstrated relatively high sensitivity and specificity in the detection of recurrence in patients with elevated thyroglobulin and negative WBS [7] .
We hereby report a patient in whom an asymptomatic non-iodine avid cerebellar metastasis from DTC was diagnosed by means of scintigraphy using somatostatin analogue Tc-99m-EDDA/HYNIC-TOC.
Patient
A 78-year-old Caucasian female was diagnosed with advanced papillary thyroid carcinoma (PTC) and subjected to total thyroidectomy with regional lymph node dissection (staging pT4N1M0), followed by L-thyroxine suppressive therapy. Subsequently, radioiodine ablation with 90 mCi was performed. The post-treatment WBS demonstrated slight radioiodine accumulation in the cervical lymph nodes, and persistent structural disease in the local lymph nodes was treated surgically. Later, radioiodine therapy was repeated twice due to persistent elevation of thyroglobulin (Tg), so the cumulative dose was 390 mCi. No specific radioiodine accumulation was found in the WBS performed seven days after recent radioiodine therapy. Neck sonography showed several enlarged hypoechogenic lymph nodes on the left side of the neck. Computed tomography of the thorax disclosed three metastatic pulmonary nodules of size less than 10 mm.
Due to poor response to radioiodine therapy, possibly caused by dedifferentiation of PTC cells, other forms of treatment had to be considered. At that time tyrosine kinase inhibitors were not regularly available for the therapy of metastatic thyroid cancer, so we needed to consider somatostatin analogues as one of the potential therapies. In order to evaluate the status of somatostatin receptors in PTC cells, a Tc-99m-EDDA/ HYNIC-TOC scan was performed.
In consistence with our protocol, the whole-body images were obtained three and 24 h after the IV injection of 20 mCi of Tc-99m-EDDA/HYNIC-TOC manufactured by Polatom, Poland. The scans were registered using an Infinia Hawkeye 4 (General Electric) gamma camera. The images showed foci of increased tracer uptake in the metastatic cervical lymph nodes and lungs, and a small focus of uptake in the head. Additional SPECT/CT of the head was performed. It showed a focus of increased tracer accumulation in the left cerebellar hemisphere 8 mm in size. (Fig. 1) .
Neurological examination did not reveal any signs of cerebellar dysfunction. As expression of somatostatin receptors was demonstrated in the metastatic foci and no radioiodine uptake was observed, experimental treatment with somatostatin analogue (Sandostatin LAR) was initiated. The therapy was well-tolerated. However, the patient died four months later at the age of 83 years due to advanced thyroid carcinoma.
Discussion
Metastases to the central nervous system among patients with DTC are extremely rare. Among 1200 patients with thyroid carcinoma treated in our institution, fewer than 1% had distant metastases detected at the time of initial diagnosis. The number of patients with distant metastases increases during follow-up and accounts for 5-10% of the patients. The most common locations are lungs (53%) and bones (28%) [8] .
Brain metastases were present in only 1.5% patients treated in M.D. Anderson Cancer Centre over 51 years [9] . Most commonly they were located in the cerebral hemispheres. The median survival was 4.7 months following the diagnosis of brain metastases [9] . Misaki et al. reported nine patients with DTC that metastasised to the brain [10] . Lack of radioiodine accumulation in
Figure 1. Focus of increased accumulation of Tc-99m-EDDA/ HYNIC-TOC in the left cerebellar hemisphere visualised in SPECT/CT representing a cerebellar metastasis of papillary thyroid carcinoma

Rycina 1. W obrazie badania SPECT/CT zwraca uwagę zwiększone gromadzenie Tc-99m-EDDA/HYNIC-TOC w lewej półkuli odpowiadające przerzutowi do móżdżku raka brodawkowego tarczycy
Tc-99m-EDDA/HYNIC-TOC scintgraphy in PTC Rafał Czepczyński et al.
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the metastases was observed by several authors [10, 11] . In some patients, the metastases were detected in cases of occult thyroid carcinoma [12, 13] . Cerebellar metastases are even less common. Only 12 cases of metastatic changes in the cerebrum from DTC were reported in the literature, some of them occurring as solitary distant metastasis [2, 3, [13] [14] [15] [16] [17] . The metastatic lesion in our patient was not solitary. For the first time, however, a previously unknown cerebellar metastasis was first demonstrated by SRS, while WBS performed after radioiodine treatment was negative.
Overexpression of somatostatin receptors, especially SSTR2, in neuroendocrine tumours is the basis for using radiolabelled analogues of this hormone for imaging purposes. For many years, In-111-DTPA-octreotide (OctreoScan) has been used in the diagnosis of neuroendocrine tumours. The sensitivity of this method reported by different authors was 51-82% in subjects presenting DTC with elevated Tg concentrations and negative WBS [18, 19] . The wide range of positive results can be attributed to study qualification criteria (stage of the disease, Tg levels) and image registration protocols.
Disadvantages of scintigraphy with In-111-DTPAoctreotide include suboptimal energy of gamma radiation emitted by In-111, higher dose equivalent obtained by patient and personnel, delayed time of acquisitions, and relatively high cost of the radiopharmaceutical. Therefore, introduction of new somatostatin analogues labelled with Tc-99m represent significant progress in endocrine oncology [6] . Decristoforo et al. and Gabriel et al. found that Tc-99m-EDDA/HYNIC-TOC scintigraphy provided superior scans and higher tumour/ background ratios than In-111-DTPA-octreotide [4, 5] . Several authors reported a high rate of positive results of scintigraphy with Tc-99m-EDDA/HYNIC-TOC or Tc-99m-EDDA/HYNIC-octreotate in different neuroendocrine tumours [20, 21] . The use of Tc-99m-EDDA/ HYNIC-TOC in advanced stages of DTC was also extensively studied. As reported by Gabriel et al., sensitivity of this imaging method in patients with non-iodine avid DTC reached 66%, but was lower than that of 18F-FDG PET [7] . Also in our centre, SRS using Tc-99m-EDDA/ HYNIC-TOC has been widely used, demonstrating encouraging results in patients with DTC, as well as with medullary thyroid carcinoma [22] . Although PET using F-18-FDG exhibits advantageous values of sensitivity and accuracy, SRS has been successfully used in our centre to evaluate the receptor status of endocrine malignancies. Similarly to neuroendocrine tumours, some of the patients with DTC were also experimentally treated with Y-90-labelled as well as with non-labelled ('cold') somatostatin analogues, with positive SRS being a major qualification criterion. Demonstration of positive status of metastatic changes for SRS was the basis for the decision on the therapy with somatostatin receptor analogues. Therefore, the authors decided that PET imaging (not widely available at the time of management) was not performed in our patient.
A limitation of our report is the lack of histopathological confirmation of the PTC origin of the brain lesion, presenting uptake of Tc-99m-EDDA/HYNIC-TOC. The patient died due to disseminated PTC, hence an autopsy was medically unwarranted. However, normal chromogranin A level, no signs of primary focus of neuroendocrine tumour, and intracerebellar localisation argue against neuroendocrine tumour metastasis or meningioma, which are the two other types of lesions potentially presenting the expression of somatostatin receptors [5, 23] .
To conclude, this report demonstrates not only an extremely rare location of DTC metastases but also the utility of SRS using technetium-labelled compound in the diagnosis of non-iodine avid metastases.
